Skip to main
  1. Stocks
  2. Axsome Therapeutics
  3. Forecast
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 47%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics is supported by a strong commercial foundation as Auvelity delivered $207.6M in 3Q26 revenue, up 53% year over year and in line with consensus, while prescriptions rose to about 302,000 and gross-to-net improved into the mid-to-high 40s. The newly approved Alzheimer’s agitation launch is gaining traction with 65+ TRx up 101% year over year and 43% quarter over quarter, suggesting a second large indication with limited competition and broad Medicare access, while Sunosi and Symbravo add steady incremental revenue. With $313.9M in cash, manageable operating expenses, and a pipeline of de-risked CNS programs including AXS-12 and solriamfetol catalysts, the company appears positioned for continued growth and cash flow positivity.

Bears say

Axsome Therapeutics is viewed negatively because its valuation is highly dependent on Auvelity while multiple pipeline assets face meaningful regulatory, clinical, and commercial execution risk. The company’s own downside case highlights that slower conversion of sampled ADA patients, payer coverage gaps, generic step-throughs, and strong competition in CNS categories could limit uptake, with Sunosi sales at $33.8M in 2Q26 and Symbravo revenue only $2.3M amid shrinking net revenue per script. AXS-14 also remains uncertain after the June 2025 Refusal to File, and the broader portfolio carries financing and dilution risk, making durable revenue growth difficult to underwrite.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 47% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction

Get the latest Axsome Therapeutics (AXSM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Axsome Therapeutics (AXSM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $258.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $258.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction

Get the latest Axsome Therapeutics (AXSM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Axsome Therapeutics (AXSM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AXSM stock data and trends